Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT04008030
TitleA Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW ) Phase
Phase 3
Date Added
2019-07-05
Location
California, United States
Colorado, United States
Illinois, United States
New York, United States
Oregon, United States
Pennsylvania, United States
Texas, United States
Virginia, United States
Argentina
Australia
Austria
Belgium
Brazil
Canada
Chile
China
Czechia
Denmark
France
Germany
Greece
Ireland
Italy
Japan
Netherlands
Norway
Puerto Rico
Romania
Spain
Turkey
United Kingdom
Prior IO Allowed
No
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Bevacizumab, cetuximab, fluorouracil, Irinotecan, Leucovorin, oxaliplatin
Tags
MSI-H/ MMRd
NCT ID
NCT04003792
TitleTreatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM. Phase
Phase 2
Date Added
2019-07-01
Location
Israel
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Bevacizumab, FOLFIRI Protocol, oxaliplatin
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03994601
TitleAn Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers Phase
Phase 1
Date Added
2019-06-21
Location
California, United States
Colorado, United States
Maryland, United States
Missouri, United States
New Jersey, United States
Argentina
Canada
Chile
France
Italy
Spain
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
BMS-986288, Nivolumab, Opdivo
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03990233
TitleA Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours Phase
Phase 1
Date Added
2019-06-18
Location
Belgium
France
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
BI 754091, BI 765063
Tags
MSS/ MMRp
NCT ID
NCT03985891
TitleThe Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer Phase
Phase 1/Phase 2
Date Added
2019-06-14
Location
China
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03984578
TitleWindow of Opportunity Study in Colorectal Cancer Phase
Phase 2
Date Added
2019-06-13
Location
Singapore
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03983993
TitleNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer Phase
Phase 2
Date Added
2019-06-12
Location
Georgia, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Niraparib, panitumumab, Vectibix, Zejula
Tags
MSS/ MMRp
NCT ID
NCT03981146
TitleA Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer Phase
Phase 2
Date Added
2019-06-10
Location
United Kingdom
Prior IO Allowed
No
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Nivolumab, Opdivo
Tags
MSS/ MMRp
NCT ID
NCT03977090
TitleGeptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal Cancer Phase
Phase 1
Date Added
2019-06-06
Location
China
Prior IO Allowed
No
CRC-directed
Yes
Status
Recruiting
Drugs
Fruquintinib, Geptanolimab Injection, Elunate
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03970382
TitleA Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors Phase
Phase 1
Date Added
2019-05-31
Location
California, United States
Illinois, United States
New York, United States
Tennessee, United States
Washington, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Suspended
Drugs
IL-2, NeoTCR-P1 adoptive cell therapy, Nivolumab
Tags
MSS/ MMRp